SCHEMBL94971

SCHEMBL94971

[CH2]c1ccc(NS(=O)(=O)c2cccc(Br)c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.65
BRD4 O60885 1/20 0.63
HSD17B2 P37059 1/20 0.59
PKM P14618 2/20 0.59
MAP4K4 O95819 1/20 0.53
PAK4 O96013 1/20 0.53
PIM1 P11309 1/20 0.53
LTK P29376 1/20 0.53
KDR P35968 1/20 0.53
MAPK14 Q16539 1/20 0.53
LRRK2 Q5S007 1/20 0.53
AURKB Q96GD4 1/20 0.53
ALK Q9UM73 1/20 0.53
PTPN2 P17706 1/20 0.53
PTPN1 P18031 1/20 0.53
PTPN5 P54829 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ADORA3 P0DMS8 1/20 0.52
SLC6A3 Q01959 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30565215 0.85 PGR (0.75) PGRBRD4HSD17B2PKMMAP4K4
SCHEMBL1403074 0.85 PGR (0.75) PGRBRD4HSD17B2PKMMAP4K4
SCHEMBL1859217 0.84 PGR (0.68) PGRBRD4HSD17B2PKMMAP4K4
SCHEMBL22441735 0.84 PGR (0.72) PGRBRD4HSD17B2PKMKDR
SCHEMBL1489068 0.84 PGR (0.65) PGRBRD4HSD17B2PKMMAP4K4
SCHEMBL28121844 0.84 PKM (0.72) PGRBRD4HSD17B2PKMMAP4K4
SCHEMBL14433749 0.83 HSD17B2 (0.66) PGRBRD4HSD17B2PKMMAP4K4
SCHEMBL95092 0.81 KMT2A (0.68) PGRPKMPTPN2PTPN1PTPN5
SCHEMBL95797 0.81 PGR (0.65) PGRPKMKDRAURKBPTPN2
SCHEMBL97999 0.81 PGR (0.73) PGRPKMKDRAURKBPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB PGR 2725/4885BRD4 590/4885HSD17B2 945/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 PGR 3206/4885BRD4 2146/4885HSD17B2 1421/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 PGR 3206/4885BRD4 2146/4885HSD17B2 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.